November 1, 2024
Macular Degeneration Articles
October 25, 2024
Gene Therapy Discussion With Drs. Kaiser and Do at AAO
By Peter K. Kaiser, MD, Diana V. Do, MD
October 18, 2024
Pegcetacoplan an Effective Treatment for Subfoveal GA
By Jim Gallagher, senior managing editor
October 18, 2024
Data Presented at AAO Support Utility of Home OCT
By Jim Gallagher, senior managing editor
October 11, 2024
My Approach to Patient Education With Avacincaptad Pegol Treatment
By Ketan G. Laud, MD
October 1, 2024
Clinical Trial Update October 2024
October 1, 2024
Results of Recent Trials of Duravyu for Wet AMD
By Carl D. Regillo, MD, FACS
October 1, 2024
A Plan for Biosimilar Integration
By Derek Burns, PharmD, MBA, BCPS, BCSCP, Lisa Lasita, PharmD, MBA
October 1, 2024
An Expanded Role for Faricimab?
By Lauren Pickel, BS, Nirojini Sivachandran, MD, PhD, FRCSC
October 1, 2024
An Expanded Role for Faricimab?
By Lauren Pickel, BS, Nirojini Sivachandran, MD, PhD, FRCSC
October 1, 2024
The Evolution of Clinical Trial Endpoints for Wet AMD
By Ruwan Amila Silva, MD, MPhil
September 26, 2024
Validating Patient Concerns Regarding Geographic Atrophy and Treatment
By Priya Vakharia, MD
September 5, 2024
Anti-complement Injections for Geographic Atrophy: A Look at the Patient and Provider Experience in my Clinic
By Tanuj Banker, MD
September 1, 2024
The Role of TNF-α Inhibitors in Managing Wet AMD
By Christian Akotoye, MD, Priya Shukla, BS, Rishi P. Singh, MD
September 1, 2024
Clinical Trial Update September 2024
September 1, 2024
New Product Applications: At-home OCT Imaging Device Approved
By Karen Appold, contributing writer
September 1, 2024
Coding Q&A: Billing for Injectable Drugs
By Brandy H. Sperry, COMT, COE, CPC, CPMA
July 25, 2024
Phase 2 LUNA Trial Data Presented at ASRS
July 25, 2024
Ellipsoid Zone Integrity at Baseline Predicts Geographic Atrophy Progression Rate
July 23, 2024
Two-year Data on Susvimo Reported at ASRS
July 17, 2024
Phase 2 PRISM Trial Data on 4D-150 Gene Therapy Presented at 2024 ASRS Meeting
By Jennifer Ford, senior managing editor
July 17, 2024
Supplemental Injection Data From DAVIO 2 Trial of EYP-1901 Presented at ASRS
By Jennifer Ford, senior managing editor
July 10, 2024
FDA Approves Anti-VEGF Biosimilar Drug
July 10, 2024
Vabysmo Prefilled Syringe Receives FDA Approval
July 1, 2024
Blue-light IOLs Reduce Progression of Macular Atrophy, But Not Incidence
By Rochelle Nataloni, contributing writer
July 1, 2024
FDA Grants De Novo Status to Notal’s Patient-operated OCT Device
July 1, 2024
PULSAR Analysis of Aflibercept in nAMD Presented at ARVO
By Rochelle Nataloni, contributing writer
July 1, 2024
Initial UK Faricimab Real-world Outcomes Presented at ARVO
By Rochelle Nataloni, contributing writer
July 1, 2024
Study: Time to First Anti-VEGF Injection in Treatment-naïve Wet AMD Patients
By Rochelle Nataloni, contributing writer
July 1, 2024
Clinical Trial Update July/August 2024
July 1, 2024
Clinical Implications of Associations Between Diabetic Retinopathy and Age-related Macular Degeneration
By Deborah Li, BA, Nicholas Fazio, BS, Michael Wolek, MD, et al.
June 27, 2024
Myth Busting Geographic Atrophy Treatment Options
By Priya Vakharia, MD
June 13, 2024
Patient Selection, Treatment Options, and Beyond With Complement Cascade Inhibitors for GA
By Daniel K. Bennett, MD
June 1, 2024
Regenxbio Publishes Data Supporting One-time Use of Gene Therapy for Wet AMD
By Rochelle Nataloni, contributing writer
June 1, 2024
Ocugen Announces Milestones in OCU410 and OCU400 Clinical Trials
By Rochelle Nataloni, contributing writer
June 1, 2024
ARCHER Trial Data Indicate ANX007 Protects Against GA Vision Loss
By Jim Gallagher, senior managing editor
June 1, 2024
Coding: Medicare Considerations of Compounded Drugs
By Brandy H. Sperry, COMT, COE, CPC, CPMA
June 1, 2024
Controversies in Care: Chlorhexidine as an Alternative to Povidone-iodine for Antisepsis Before Intravitreal Injection
By Michael Colucciello, MD, Jason Fan, MD, PhD, Harry W. Flynn Jr., MD, et al.
June 1, 2024
Clinical Trial Update June 2024
June 1, 2024
FDA Approves First Biosimilars to Eylea
By Jim Gallagher, senior managing editor
May 1, 2024
Overview of Retinal Prosthesis and Future Directions
By Jade Y. Moon, MD, Richard N. Sather III, BS, Sandra R. Montezuma, MD
May 1, 2024
Clinical Trial Update May 2024
May 1, 2024
Current State of Telemonitoring in Retina
By Miguel A. Busquets, MD, Matthew Trese, DO
May 1, 2024
New Product Applications: Lengthening the Time Between Treatments
By Karen Appold, contributing writer
May 1, 2024
Subspecialty News May 2024
By Rochelle Nataloni, contributing writer
May 1, 2024
Upfront: The Technological Intersection of Aviation and Retina
By Peter K. Kaiser, MD
May 1, 2024
New Growth in Low-vision Assistive Technology
By Thomas A. Finley, MD
April 29, 2024
AMARONE Shows Promising Outcomes for a Novel Treatment Pathway in DME and nAMD
By Charles C. Wykoff, MD, PhD, Michael A. Singer, MD
April 1, 2024
Upfront: Innovations in VEGF Inhibition Delivery
By Peter K. Kaiser, MD
April 1, 2024
Clinical Trial Update April 2024
April 1, 2024
Improving Durability of Drugs in Wet AMD
By Lucas W. Rowe, MD, Thomas A. Ciulla, MD, MBA
April 1, 2024
Subspecialty News April 2024
By Rochelle Nataloni, contributing writer
April 1, 2024
Tyrosine Kinase Inhibitors for Wet AMD and Diabetic Retinopathy
By Nikhil Das, MD, Katherine E. Talcott, MD
April 1, 2024
Broader VEGF Pathway Inhibition for Wet AMD
By Mark R. Barakat, MD, Mark P. Breazzano, MD
April 1, 2024
Gene Therapy for Wet Age-related Macular Degeneration
By Khiem Sy Nguyen, BS, Samaantar Joshi, BS, Karen M. Wai, MD, et al.
March 25, 2024
Positive Results for EYP-1901 in DAVIO 2, and a Look Forward to Phase 3
By Carl D. Regillo, MD, FACS, Michael A. Singer, MD
March 1, 2024
Clinical Trial Update March 2024
March 1, 2024
Clinical Trial Download: Longer-term Data on New Treatments for Geographic Atrophy
By Yasha Modi, MD , Vaidehi S. Dedania, MD, Talia R. Kaden, MD
March 1, 2024
Cost Effectiveness of Early Detection of Wet Age-related Macular Degeneration
By Samaantar Joshi, BS, Khiem Sy Nguyen, BS, Karen M. Wai, MD, et al.
March 1, 2024
Considerations in Management of Dry AMD
By Karen W. Jeng-Miller, MD, MPH
March 1, 2024
Imaging Features That Portend Development of Geographic Atrophy
By Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, Zhichao Wu, BAppSc (Optom), PhD
March 1, 2024
Subspecialty News March 2024
By Rochelle Nataloni, contributing writer
February 16, 2024
Retinal Physician eUpdate - February 16, 2024
By Steve Lenier
January 1, 2024
Artificial Intelligence to Manage the AMD Burden
By William Haseltine, PhD, Kim Hazel, MPH
January 1, 2024
Peripheral Retinal Changes in AMD
By Melissa Yuan, MD, Ines Lains, MD, PhD
January 1, 2024
Insightful Imaging for Geographic Atrophy
By Brian Solinsky, MD, Eliza Broadbent, BS, Elias Siltanen, BS, et al.
January 1, 2024
Subspecialty News January/February 2024
By Rochelle Nataloni, contributing writer
January 1, 2024
EyePoint Reports Positive Results of Phase 2 Trial for Investigational AMD Treatment
By Jim Gallagher, senior managing editor
January 1, 2024
Show Daily Coverage From the American Academy of Ophthalmology 2023 Annual Meeting
By Steve Lenier
January 1, 2024
Clinical Trial Update January/February 2024
January 1, 2024
CONTROVERSIES IN CARE: Withdrawal of Anti-VEGF Agents in Neovascular AMD
By Michael Colucciello, MD, Anat Loewenstein, MD, MHA, Diana V. Do, MD
November 1, 2023
SUBSPECIALTY NEWS: Ryzumvi approved, positive gene therapy data, Syfovre receives J code, and more.
By Rochelle Nataloni, contributing writer
November 1, 2023
NEW PRODUCT APPLICATIONS: Drug Slows the Progression of Geographic Atrophy
By Karen Appold, contributing writer
November 1, 2023
Clinical Trial Update November/December 2023
October 1, 2023
SUBSPECIALTY NEWS: Biosimilar FDA application hits roadblock, Apellis provides guidance on Syfovre use, and more.
By Rochelle Nataloni, contributing writer
October 1, 2023
CLINICAL TRIAL DOWNLOAD: Twelve-month Data From a Phase 1 Clinical Trial of OTX-TKI for Wet AMD
By Arshad M. Khanani, MD, MA, FASRS, Paula Pecen, MD, Rabia Gurses Ozden, MD
October 1, 2023
NEW PRODUCT APPLICATIONS: Optos Retinal Imaging System Offers New Color Modality
By Karen Appold, contributing writer
October 1, 2023
Clinical Trial Update October 2023
October 1, 2023
Clinical Pearls for Newly Approved Treatments for GA
By Aamir A. Aziz, BS, Carl Danzig, MD
September 1, 2023
Systemic Medications and Lifestyle Factors in AMD
By John Moir, BA, Sarthak Aggarwal, BS, Dimitra Skondra, MD, PhD
September 1, 2023
Managing Treatment Resistance in Neovascular Age-related Macular Degeneration
By Asad F. Durrani, MD, Yoshihiro Yonekawa, MD
September 1, 2023
Glycoimmune Therapy as a Novel Treatment Approach for Geographic Atrophy
By Sophie J. Bakri, MD, MBA, Jeffrey S. Heier, MD, Arshad M. Khanani, MD, MA, FASRS, et al.
September 1, 2023
Bispecific Antibodies in Retina Therapies
By René Rückert, MD, MBA, Gemmy Cheung Chui Ming, FRCOphth, Marion R. Munk, MD, PhD, FEBO
September 1, 2023
The Current Landscape of Anti-VEGF Biosimilars
By Angela S. Li, MD, Sharon Fekrat, MD, FASRS
September 1, 2023
SUBSPECIALTY NEWS: Izervay FDA approval, ReST committee updates on Syfovre, and more.
By Rochelle Nataloni, contributing writer
September 1, 2023
CLINICAL TRIAL DOWNLOAD: LIGHTSITE III 24-month Photobiomodulation Results
By Yasha Modi, MD , Matthew W. Russell, MD, Rishi P. Singh, MD, et al.
September 1, 2023
Clinical Trial Update September 2023
August 22, 2023
Eylea HD 8-mg Injection Approved for Wet AMD, DME, and DR
By Jennifer Ford, senior managing editor
August 7, 2023
Iveric Bio's Izervay Receives FDA Approval as Treatment for Geographic Atrophy
By Jennifer Ford, senior managing editor
July 1, 2023
SUBSPECIALTY NEWS: Mydriasis spray approved, laser and imaging devices cleared, new AI technology, and more.
By Rochelle Nataloni, contributing writer
July 1, 2023
Clinical Trial Update July/August 2023
June 1, 2023
SUBSPECIALTY NEWS: New product launches in laser and surgery, progress on clinical trials in dry AMD, and more.
By Rochelle Nataloni, contributing writer
June 1, 2023
Clinical Trial Update June 2023
May 1, 2023
An Update on Stem Cell Therapy for Retinal Diseases
By Samuel R. Feldman, MD, Glenn C. Yiu, MD, PhD, Susanna S. Park, MD, PhD
May 1, 2023
Home Monitoring for Neovascular AMD Conversion
By SIDNEY A. SCHECHET, MD
May 1, 2023
Polymers for Retinal Drug Delivery
By Charles D. Blizzard, Dina Akasheh, PhD, Matthew Cheung, PharmD, et al.
May 1, 2023
SUBSPECIALTY NEWS: Retina changes seen in Alzheimer disease, research into new GA therapies, and more.
By Rochelle Nataloni, contributing writer
May 1, 2023
NEW PRODUCT APPLICATIONS: The First Drug to Treat Geographic Atrophy Debuts
By Karen Appold, contributing writer
May 1, 2023
Clinical Trial Update May 2023
April 1, 2023
Retina Clinic Considerations in the Era of Treatment for Advanced Dry AMD
By Yingna Liu, MD, Roger A. Goldberg, MD, MBA
April 1, 2023
Current Status of Subretinal Delivery Devices
By Prethy Rao, MD, MPH, Edward Wood, MD, Tamer Mahmoud, MD, PhD
April 1, 2023
UPFRONT: The Beginning of Geographic Atrophy Treatment
By Peter K. Kaiser, MD
April 1, 2023
SUBSPECIALTY NEWS: Early anti-VEGF for DR shows no benefit, developments in gene therapy, research on IRD, and more.
By Rochelle Nataloni, contributing writer
April 1, 2023
Clinical Trial Update April 2023
March 1, 2023
A Basic Primer on Gene Therapy
By Thomas A. Ciulla, MD, MBA, Aumer Shughoury, MD
March 1, 2023
Gene Therapy for Dry AMD
By Ehsan Rahimy, MD, Austen N. Knapp, MD
March 1, 2023
Update on Optogenetics for Advanced Retinal Degenerations
By Joseph Martel, MD, Jose-Alain Sahel, MD
March 1, 2023
Current Challenges in Gene Therapy Trials
By Glenn C. Yiu, MD, PhD, Arshad M. Khanani, MD, MA, FASRS, Kathryn L. Pepple, MD, PhD
March 1, 2023
UPFRONT: Gene Therapy's Price Tag
By Peter K. Kaiser, MD
March 1, 2023
SUBSPECIALTY NEWS: First drug approved for ROP, PDT laser approved, inequities in ophthalmology research, and more.
By Rochelle Nataloni, contributing writer
March 1, 2023
NEW PRODUCT APPLICATIONS: Ranibizumab Biosimilar Offers Lower-price Treatment Option
By Karen Appold, contributing writer
March 1, 2023
Clinical Trial Update March 2023
February 2, 2023
FDA Approves Syfovre as First Treatment for Geographic Atrophy
February 1, 2023
UPFRONT: Evolution of Retina Clinical Trials to Target Geographic Atrophy
By Peter K. Kaiser, MD
February 1, 2023
GUEST EDITORIAL: At the Brink of a Dry AMD Revolution
By Eleonora Lad, MD, PhD
February 1, 2023
SUBSPECIALTY NEWS: Methotrexate for vitreoretinal lymphoma, drugs for retinitis pigmentosa, AI technology in retina, and more.
By Rochelle Nataloni, contributing writer
February 1, 2023
NEW PRODUCT APPLICATIONS: Platform Combines Multiple Testing Modalities Into One Device
By Karen Appold, contributing writer
February 1, 2023
Clinical Trial Update: Special Edition 2023
January 1, 2023
Artificial Intelligence and Augmented Intelligence in Ophthalmic Practice
By Miguel A. Busquets, MD
January 1, 2023
Retinal Fluid Fluctuations in the Treatment of Neovascular AMD
By Veeral S. Sheth, MD, MBA, FACS, Rhianon Reynolds, MD
January 1, 2023
SUBSPECIALTY NEWS: Progress toward GA drug approval, new gene therapy data, and more.
By Rochelle Nataloni, contributing writer
January 1, 2023
CONTROVERSIES IN CARE: Macular Atrophy Associated With Anti-VEGF Therapy for Wet AMD
By Michael Colucciello, MD, Jayanth Sridhar, MD, Anton Kolomeyer, MD, PhD
January 1, 2023
CLINICAL TRIAL DOWNLOAD: High-dose Aflibercept for Wet AMD and DME
By Yasha Modi, MD , PAOLO LANZETTA, MD, David Brown, MD
January 1, 2023
Clinical Trial Update January/February 2023
November 1, 2022
Retina Specialist and Optometrist Comanagement of AMD Patients
By Jeffry D. Gerson, OD, FAAO, Rishi P. Singh, MD
November 1, 2022
Remote Monitoring to Track Fellow Eye AMD Progression
By Miguel A. Busquets, MD
November 1, 2022
SUBSPECIALTY NEWS: New data presented at AAO in dry AMD, ocular oncology, gene therapy, and more.
By Rochelle Nataloni, contributing writer
November 1, 2022
CONTROVERSIES IN CARE: Examining the Evidence for Macular Atrophy as a Complication of Anti-VEGF Therapy for Wet AMD
By Michael Colucciello, MD
November 1, 2022
Clinical Trial Update November/December 2022
October 1, 2022
Sustained-release Tyrosine Kinase Inhibitors for the Treatment of nAMD
By Arshad M. Khanani, MD, MA, FASRS, Carl D. Regillo, MD, FACS, Charles C. Wykoff, MD, PhD, et al.
October 1, 2022
UPFRONT: Targeting Tyrosine Kinases in Retinal Disease
By Peter K. Kaiser, MD
October 1, 2022
SUBSPECIALTY NEWS: FDA approves Cimerli, GATHER2 GA trial meets primary endpoint, and more.
By Rochelle Nataloni, contributing writer
October 1, 2022
CLINICAL TRIAL DOWNLOAD: Data From the Phase 2b Trial of OPT-302
By Yasha Modi, MD , Jason S. Slakter, MD, Aleksandra V. Rachitskaya, MD, FASRS, et al.
October 1, 2022
Clinical Trial Update October 2022
September 1, 2022
SUBSPECIALTY NEWS: Pegcetacoplan gets priority review, Eva Nexus injector cleared, Eylea extended dosing under review, and more.
By Rochelle Nataloni, contributing writer
September 1, 2022
Clinical Trial Update September 2022
August 1, 2022
Suprachoroidal Drug Delivery Technology
By Thomas A. Ciulla, MD, MBA, Rafael V. Andino, MSBE, MBA, Shelley Hancock, MBA
August 1, 2022
SUBSPECIALTY NEWS: Data presented on THR-149 and THR-687 for DME, pegcetacoplan NDA submitted, AREDS2 benefit confirmed, and more.
By Rochelle Nataloni, contributing writer
August 1, 2022
Clinical Trial Update Special Edition 2022
July 1, 2022
Oral Drug Pipeline for Retinal Disease
By Charles DeBoer, MD, PhD, Suzanne Michalak, MD, Ehsan Rahimy, MD
July 1, 2022
The Importance of Early Referral for Neovascular AMD
By Miguel A. Busquets, MD
July 1, 2022
Potential Implications of Silicone Oil From Syringes
By Gustavo B. Melo, MD, PhD, FASRS
July 1, 2022
SUBSPECIALTY NEWS: RetinAI gets FDA clearance, suprachoroidal therapy update, GA trial data, and more.
By Rochelle Nataloni, contributing writer
July 1, 2022
Clinical Trial Update July/August 2022
June 1, 2022
SUBSPECIALTY NEWS: Geographic atrophy quality-of-life survey, Xipere launch, ophthalmic bevacizumab FDA application, and more.
By Rochelle Nataloni, contributing writer
June 1, 2022
Clinical Trial Update June 2022
May 1, 2022
Discordances in Perceptions of Shared Decision-making Among Patients With Retinal Diseases and Their Care Teams
By John S. Pollack, MD, W. Lloyd Clark, MD, Darius M. Moshfeghi, MD, et al.
May 1, 2022
SUBSPECIALTY NEWS: Geographic atrophy lesion growth slowed with pegcetacoplan, new data on extended-duration therapies, and more.
By Rochelle Nataloni, contributing writer
May 1, 2022
Clinical Trial Update May 2022
April 1, 2022
Early-phase Drugs in Development for Dry AMD
By William Carrera, MD, MS, Roger A. Goldberg, MD, MBA
April 1, 2022
Treating AMD at the Intermediate Level
By Carla Danese, MD, PAOLO LANZETTA, MD
April 1, 2022
The Current Landscape of Intravitreal Treatments for Neovascular AMD
By Matias Iglicki, MD, Anat Loewenstein, MD, MHA, Dinah Zur, MD
April 1, 2022
SUBSPECIALTY NEWS: FDA approves uveal melanoma treatment, sepofarsen fails to meet endpoints, and more.
By Rochelle Nataloni, contributing writer
April 1, 2022
Clinical Trial Update April 2022
March 1, 2022
Intraocular Inflammation Associated With Current and Prospective Therapies for Patients With Wet AMD
By Andreas M. Wingert, Jayanth Sridhar, MD
March 1, 2022
SUBSPECIALTY NEWS: Results in suprachoroidal trial, RNA therapy for RP, Beovu in DME, and more.
By Rochelle Nataloni, contributing writer
March 1, 2022
Clinical Trial Update March 2022
February 1, 2022
Faricimab Approved by the FDA for Wet AMD and DME
By Rochelle Nataloni, contributing writer
January 1, 2022
A Review of Mitochondrial Flavoprotein Fluorescence for Retinal Metabolic Imaging
By Matthew W. Russell, MD, Justin C. Muste, MD, Rishi P. Singh, MD
January 1, 2022
Practical Tips for Capturing and Interpreting OCT Angiography Images
By S. Tammy Hsu, MD, Lejla Vajzovic, MD, FASRS
January 1, 2022
SUBSPECIALTY NEWS: Real-world Iluvien data, advances to program for choroidal melanoma treatment, results for at-home OCT, and more.
By Rochelle Nataloni, contributing writer
January 1, 2022
Clinical Trial Update January/February 2022
Advertisement
Recommendations
Advertisement